PGE(2)-induced lasting nociception to heat: evidences for a selective involvement of A-delta fibres in the hyperpathic component of hyperalgesia.
Animal models for mechanical pressure or heat nociception usually only measure the threshold response latency. In this study, the effect of typical sensitising treatments on the lasting nocifensive behaviour elicited after a supra-threshold heating stimulus - the hyperpathic component of hypernociception - was assessed. Male Wistar rats received either intra-plantar (i.pl.) injection of 350ng PGE(2) (50microL) or topical application (t.a.) of 100% dimethylsulfoxide (DMSO), and 10mM capsaicin. One hour after the paw treatments the number of nocifensive events (NNE) was scored hourly (6h), for 5min, immediately after a hind paw immersion in hot water (50 degrees C/7s). PGE(2), DMSO and capsaicin increased the NNE -induced by the supra-threshold stimuli. Indomethacin (2.5mg/kg i.p.), given 30min before paw treatments, completely inhibited NNE in all groups (P<0.01). However, indomethacin given 60min after PGE(2) did not reverse this sensitisation. PGE(2) and DMSO did not lower the heat threshold in the paw withdrawal test, although carrageenan and capsaicin were effective (P<0.05). Capsaicin neonatal treatment (CNT) (50mg/kg) reduced the sensitisation induced by DMSO and capsaicin (P<0.01), but not that induced by PGE(2). These data suggest that the heat-induced lasting nociception is probably conveyed by Aeth nociceptors, and PGE(2) seems to be more selective to induce this phenomenon than the thermal threshold lowering. In addition, this hyperpathic effect induced by DMSO and capsaicin seems to be indirectly mediated by PGE(2) and C-fibres.
Department of Pharmacology, Federal University of Santa Catarina, Florianópolis - Santa Catarina 88040-900, Brazil.
Lúcia C
LC
Bastos
Carlos R
CR
Tonussi
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002211:Capsaicin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004121:Dimethyl Sulfoxide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006358:Hot Temperature; D006930:Hyperalgesia / Q000473:pathology*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000473:pathology* / Q000502:physiology; D036421:Nerve Fibers, Unmyelinated / Q000187:drug effects / Q000473:pathology; D009619:Nociceptors / Q000187:drug effects; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology*; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015232:Dinoprostone; D002211:Capsaicin; D007213:Indomethacin; D004121:Dimethyl Sulfoxide